ClinicalTrials.gg
CompletedNCT00652145DEARUpdated May 5, 2015Results posted

Dose Escalation and Remission (DEAR)

A Phase 4 interventional study of mesalamine in Ulcerative Colitis, sponsored by James Lewis. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-05.

Sponsored by James Lewis · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing mesalamine in Colitis, Ulcerative — 5 open to participants now, 6 under way, 1 of them phase 3. Mesalamine · Colitis, Ulcerative.

Enrollment
30th of 49
119 · median 206
Started
2008
with 3 others
Phase 4
13 of 50
3 open now
Registered
19th of 50
by date

Among the 50 studies testing mesalamine in Colitis, Ulcerative, this one is the 30th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2008, is one of 13 in phase 4, and was the 19th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 50 studies testing mesalamine in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mesalamine

Mesalamine: first FDA approval 1987 (ROWASA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing mesalamine in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels \<50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.

Read the detailed description

Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse. We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC.

We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC >50 µg/g, and intake of no more than 3 g/day mesalamine. Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine (2.4 g/day) for 6 weeks; 52 participants were then randomly assigned (1:1) to a group that continued its current dose of mesalamine (controls, n = 26) or a group that increased its dose by 2.4 g/day for 6 weeks (n = 26). The primary outcome was continued remission with FC \<50 µg/g. Secondary outcomes were continued remission with FC \<100 µg/g or \<200 µg/g (among patients with pre-randomization values above these levels).

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • ulcerative colitis
  • inflammatory bowel disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and sign the form.
  2. Have documented ulcerative colitis on the basis of usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology.
  3. Have a Simple Clinical Colitis Activity Index (SCCAI)55 score below 3 with no category value greater than 1 (Table 5).
  4. Three or fewer bowel movements per 24 hours at the time of enrollment.
  5. No visible blood in their bowel movements in the three days prior to enrollment.
  6. Have either been on a stable dose of mesalamine medication (oral, rectal or a combination of oral and rectal, including sulfasalazine) or on no mesalamine medications for at least 4 weeks prior to enrollment.
  7. Have been on either a stable dose of azathioprine, 6-mercaptopurine, or methotrexate or on none of these medications for at least 8 weeks prior to enrollment.
  8. Have experienced at least one flare of ulcerative colitis in the 2 years prior to enrollment. A flare is defined as an increase in stool frequency, bleeding, urgency and/or abdominal discomfort sufficient to warrant a change in medication dose or addition of a new medication.
  9. Most recently measured serum creatinine level in the preceding year less than 1.5 mg/dL.

Exclusion criteria

Exclusion Criteria:

  1. Age less than 18
  2. Inability to speak and read English
  3. Presence of an ostomy or prior total or subtotal colectomy
  4. Current use or use within the two weeks prior to enrollment
  5. Remission for less than 4 weeks prior to enrollment
  6. Previous intolerance to mesalamine at doses greater than the current dose.
  7. Use of rectally administered mesalamine or steroids within the 2 weeks prior to enrollment.
  8. Currently taking more than 3.0 gm/day of mesalamine (oral or rectal). If on oral and rectal mesalamine, the combined dose is more than 3.0 gm/day.
  9. Use of anti-TNFα therapies within the 8 weeks prior to enrollment and/or intent to use anti-TNFα therapies as maintenance therapy in the coming 12 weeks.
  10. Pregnant or breast feeding women.
  11. Use of an experimental therapy for ulcerative colitis in the 8 weeks prior to enrollment.
  12. Any condition that the investigator feels will make completion of the study unlikely.
  13. Use of cyclosporine in the two weeks prior to enrollment.
  14. Moderate or severe abdominal tenderness on examination at time of enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Increase mesalamine dose by 2.4g/day

    Increase dose of mesalamine by 2.4 gm per day

    Drug: mesalamine

  • No intervention
    Maintain mesalmine dose

    Maintain current mesalamine dose at 2.4 g/day

Interventions

  • Increase dose by 2.4gm per day over baseline dose

    Also known as: Lialda

06

What researchers measure

Primary outcomes

  1. Fecal Calprotectin Level <50µg/g

    Time frame: 6 weeks after randomization

Secondary outcomes

  1. Fecal Calprotectin Level <100 µg/g

    Time frame: at 6 weeks after randomization

  2. Fecal Calprotectin <200 µg/g

    Time frame: at 6 weeks after randomization

07

Results

Posted May 5, 2015

Participant flow

We screened 150 patients and enrolled 119 patients with UC in remission on the basis of SCCAI score. 58 patients had baseline fecal calprotectin(FC) \<50 µg/g. These patients were followed in an observational arm. 61 had FC \>= 50 µg/g,whose current mesalamine dose \<3g/day. See preassignment details.

Participant flow — Overall Study
MilestoneIncrease Dose of MesalamineMaintain Baseline Mesalamine Dose
Started2626
Completed2626
Not completed00

Outcome measures

PrimaryFecal Calprotectin Level <50µg/g
Time frame:
6 weeks after randomization
Reported as:
Number · participants
Fecal Calprotectin Level <50µg/g
participantsIncrease Mesalamine Dose by 2.4g/DayMaintain Mesalmine Dose
Fecal Calprotectin Level <50µg/g71
SecondaryFecal Calprotectin Level <100 µg/g
Time frame:
at 6 weeks after randomization
Reported as:
Number · participants
Fecal Calprotectin Level <100 µg/g
participantsIncrease Dose of MesalamineMaintain Baseline Mesalamine Dose
Fecal Calprotectin Level <100 µg/g103
SecondaryFecal Calprotectin <200 µg/g
Time frame:
at 6 weeks after randomization
Reported as:
Number · participants
Fecal Calprotectin <200 µg/g
participantsIncrease Dose of MesalamineMaintain Baseline Mesalamine Dose
Fecal Calprotectin <200 µg/g102

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Increase Dose of Mesalamine—0/26 (0%)11/26 (42.3%)
Maintain Baseline Mesalamine Dose—0/26 (0%)7/26 (26.9%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventIncrease Dose of MesalamineMaintain Baseline Mesalamine Dose
diarrheaGastrointestinal disorders3/261/26
blood in stoolGastrointestinal disorders1/262/26
BloatingGastrointestinal disorders2/260/26
Abdominal painGastrointestinal disorders0/261/26
acneSkin and subcutaneous tissue disorders0/261/26
ConstipationGastrointestinal disorders0/261/26
dizzinessGeneral disorders1/260/26
FatigueGeneral disorders1/260/26
FeverInfections and infestations1/260/26
FlatulenceGastrointestinal disorders1/261/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
Median43.8 (30.5 to 57.1)48.8 (33.5 to 60.4)46.5 (32.0 to 58.0)
Sex: Female, Male
Sex: Female, Male(Participants)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
Female111324
Male151328
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
American Indian or Alaska Native101
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American246
White222143
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
United States262652
Tobacco use
Tobacco use(participants)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
Current022
Prior6814
Never201636
Extent of disease
Extent of disease(participants)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
Proctitis8210
Left-sided91221
Extensive91120
Other011
Median duration of UC
Median duration of UC(years)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
Median11.9 (3.7 to 19.8)6.5 (2.2 to 11.9)8.9 (2.8 to 15.9)
Median of duration of remission at baseline
Median of duration of remission at baseline(years)Increase Mesalamine DoseMaintain Mesalamine DoseTotal
Median0.3 (0.2 to 1.0)0.5 (0.2 to 1.1)0.4 (0.2 to 1.0)

8 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55446, United States
  • South Jersey Gastroenterology
    Marlton, New Jersey 08053, United States
  • University of Pennsylvania - Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035. Epub 2014 Apr 30. PubMed 24793028 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 3, 2008
Start
Sep 2008
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
May 5, 2015
Last update
May 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00652145
Lead sponsor
James Lewis
Responsible party
James Lewis (Professor of Medicine and Epidemiology, University of Pennsylvania) — Sponsor-investigator
First posted
Apr 3, 2008
Start date
Sep 2008
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
May 5, 2015
Last update
May 5, 2015

Study contacts

James D Lewis, MD, MSCE
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesalamine

Start the discussion